Jinsong Wu's study provides a higher level (IIb) of evidence for the correlation between IDH mutations and the responsiveness to up-front adjuvant metronomic temozolomide chemotherapy in young patients with low grade gliomas located in eloquent brain areas (42). The gene discussed is IDH1; the disease is glioma.